Gilead Sciences’ decision to expand a licensing agreement that will allow generic companies to sell low-cost versions of its HIV and hepatitis C generic drugs in Malaysia, Thailand, Ukraine and Belarus has drawn a muted response from medicine access campaigners.
The company is being accused of taking this long overdue “positive step for patients” under pressure from the Malaysian government,...





